Synergistic repression of estrogen receptor transcriptional activity by FHL2 and Smad4 in breast cancer cells

IUBMB Life

Volumn 62, Issue 9, 2010, Pages 669-676

  Xiong, Zhihong ^a   Ding, Lihua ^a   Sun, Junzhong ^b   Cao, Jia ^a   Lin, Jing ^b   Lu, Zhaohui ^b   Liu, Yufei ^a   Huang, Cuifen ^a   Ye, Qinong ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Estrogen receptor; Estrogen signaling; Four and a half LIM domain protein 2; Interaction; Smad4

Indexed keywords

CATHEPSIN D; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; FOUR AND A HALF LIM DOMAIN PROTEIN 2; MUTANT PROTEIN; REGULATOR PROTEIN; SMAD4 PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; GENE DELETION; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MUSCLE PROTEINS; RECEPTORS, ESTROGEN; SMAD4 PROTEIN; TRANSCRIPTION FACTORS;

EID: 78649729955     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.367     Document Type: Article

References (37)

1. Genini, M., Schwalbe, P., Scholl, F. A., Remppis, A., Mattei, M. G., and Schäfer, B.W. (1997) Subtractive cloning and characterization of DRAL, a novel LIM-domain protein down-regulated in rhabdomyosarcoma. DNA Cell. Biol. 16, 433-442.
2. Johannessen, M., Møller, S., Hansen, T., Moens, U., and Van Ghelue, M.(2006) The multifunctional roles of the four-and-a-half-LIM only protein FHL2. Cell. Mol. Life Sci. 63, 268-284.
3. Müller, J. M., Isele, U., Metzger, E., Rempel, A., Moser, M., Pscherer A., Breyer, T., Holubarsch, C., Buettner, R., and Schüle R. (2000) FHL2, a novel tissue-specific coactivator of the androgen receptor. EMBO J. 19, 359-369.
4. Morlon, A., and Sassone-Corsi, P. (2003) The LIM-only protein FHL2 is a serum-inducible transcriptional coactivator of AP-1. Proc. Natl. Acad. Sci. USA 100, 3977-3982.
5. McLoughlin, P., Ehler, E., Carlile, G., Licht, J. D., and Schäfer, B. W. (2002) The LIM-only protein DRAL/FHL2 interacts with and is a corepressor for the promyelocytic leukemia zinc finger protein. J. Biol. Chem. 277, 37045-37053.
6. Hill, A. A., and Riley, P. R. (2004) Differential regulation of Hand1 homodimer and Hand1-E12 heterodimer activity by the cofactor FHL2. Mol. Cell. Biol. 24, 9835-9847.
7. Kobayashi, S., Shibata, H., Yokota, K., Suda, N., Murai, A., Kurihara, I., Saito, I., and Saruta, T. (2004) FHL2, UBC9, and PIAS1 are novel estrogen receptor a-interacting proteins. Endocr. Res. 30, 617-621.
8. Hanstein, B., Djahansouzi, S., Dall, P., Beckmann, M. W., and Bender, H. G. (2004) Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer. Eur. J. Endocrinol. 150, 243-255.
9. Hayashi, S. I., Eguchi, H., Tanimoto, K., Yoshida, T., Omoto, Y., Inoue, A., Yoshida, N., and Yamaguchi, Y. (2003) The expression and function of estrogen receptor and in human breast cancer and its clinical application. Endocr. Relat. Cancer 10, 193-202.
10. Carroll, J. S., and Brown, M. (2006) Estrogen receptor target gene: An evolving concept. Mol. Endocrinol. 20, 1707-2714.
11. Deroo, B. J., and Korach, K. S. (2006) Estrogen receptors and human disease. J. Clin. Invest. 116, 561-570.
12. Massagué, J., Seoane, J., and Wotton, D. (2005) Smad transcription factors. Genes Dev. 19, 2783-2810.
13. Stuelten, C. H., Buck, M. B., Dippon, J., Roberts, A. B., Fritz, P., and Knabbe, C. (2006) Smad4-expression is decreased in breast cancer tissues: A retrospective study. BMC Cancer 6, 25.
14. Deckers, M., van Dinther, M., Buijs, J., Que, I., Löwik, C., van der Pluijm, G., and ten Dijke, P. (2006) The tumor suppressor Smad4 is required for transforming growth factor β-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res. 66, 2202-2209.
15. Kang, Y., He, W., Tulley, S., Gupta, G. P., Serganova, I., Chen, C. R., Manova-Todorova, K., Blasberg, R., Gerald, W. L., and Massagué, J. (2005) Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. USA 102, 13909-13914.
16. Liberati, N. T., Datto, M. B., Frederick, J. P., Shen, X., Wong, C., Rougier- Chapman, E. M., and Wang, X. F. (1999) Smads bind directly to the Jun family of AP-1 transcription factors. Proc. Natl. Acad. Sci. USA 96, 4844-4849.
17. Chipuk, J. E., Cornelius, S. C., Pultz, N. J., Jorgensen, J. S., Bonham, M. J., Kim, S. J., and Danielpour, D. (2002) The androgen receptor represses transforming growth factor-b signaling through interaction with Smad3. J. Biol. Chem. 277, 1240-1248.
18. Feng, X. H., Zhang, Y., Wu, R. Y., and Derynck, R. (1998) The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF-β-induced transcriptional activation. Genes Dev. 12, 2153-2163.
19. Wu, L., Wu, Y., Gathings, B., Wan, M., Li, X., Grizzle, W., Liu, Z., Lu, C., Mao, Z., and Cao, X. (2003) Smad4 as a transcription corepressor for estrogen receptor α. J. Biol. Chem. 278, 15192-15200.
20. Zhang, H., Xie, X., Zhu, X., Zhu, J., Hao, C., Lu, Q., Ding, L., Liu, Y., Zhou, L., Liu, Y., Huang, C., Wen, C., and Ye, Q. (2005) Stimulatory cross-talk between NFAT3 and estrogen receptor in breast cancer cells. J. Biol. Chem. 280, 43188-43197.
21. Ding, L., Wang, Z., Yan, J., Yang, X., Liu, A., Qiu, W., Zhu, J., Han, J., Zhang, H., Lin, J., Cheng, .L, Qin, X., Niu, C., Yuan, B., Wang, X., Zhu, C., Zhou, Y., Li, J., Song, H., Huang, C., and Ye, Q. (2009) Human fourand- a-half LIM family members suppress tumor cell growth through a TGF-b-like signaling pathway. J. Clin. Invest. 119, 349-361.
22. Wang, X., Yang, Z., Zhang, H., Ding, L., Li, X., Zhu, C., Zheng, Y., and Ye, Q. (2008) The estrogen receptor-interacting protein HPIP increases estrogen-responsive gene expression through activation of MAPK and AKT. Biochim. Biophys. Acta 1783, 1220-1228.
23. Qin, X., Wang, X. H., Yang, Z. H., Ding, L. H., Xu, X. J., Cheng, L., Niu, C., Sun, H. W., Zhang, H., and Ye, Q. N. (2008) Repression of NFAT3 transcriptional activity by estrogen receptors. Cell. Mol. Life Sci. 65, 2752-2762.
24. Klinge, C. M. (2001) Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res. 29, 2905-2919.
25. Helguero, L. A, Faulds, M. H., Gustafsson, J. A., and Haldosen L. A. (2005) Estrogen receptors (ERa and ERb) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 24, 6605-6616.
26. Omoto, Y., Eguchi, H., Yamamoto-Yamaguchi, Y., and Hayashi, S. (2003) Estrogen receptor (ER) b1 and ERbcx/b2 inhibit ERa function differently in breast cancer cell line MCF7. Oncogene 22, 5011-5020.
27. Stossi, F., Barnett, D. H., Frasor, J., Komm, B., Lyttle, C. R., and Katzenellenbogen, B. S. (2004) Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) a or ERb in human osteosarcoma cells: Distinct and common target genes for these receptors. Endocrinology 145, 3473-3486.
28. Kleiber, K., Strebhardt, K., and Martin, B. T. (2007) The biological relevance of FHL2 in tumour cells and its role as a putative cancer target. Anticancer Res. 27, 55-61.
29. Gabriel, B., Mildenberger, S., Weisser, C W., Metzger, E., Gitsch, G., Schüle, R., and Mü ller, J. M. (2004) Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer. Anticancer Res. 24, 921-927.
30. Tanahashi, H., and Tabira, T. (2000) Alzheimer's disease-associated presenilin 2 interacts with DRAL, an LIM-domain protein. Hum. Mol. Genet. 9, 2281-2289.
31. Chan, K. K., Tsui, S. K., Ngai, S. M., Lee, S. M., Kotaka, M., Waye, M. M., Lee, C. Y., and Fung, K. P. (2000) Protein-protein interaction of FHL2, a LIM domain protein preferentially expressed in human heart, with hCDC47. J. Cell. Biochem. 76, 499-508.
32. Chen, D., Xu, W., Bales, E., Colmenares, C., Conacci-Sorrell, M., Ishii, S., Stavnezer, E., Campisi, J., Fisher, D. E., Ben-Ze'ev, A., and Medrano, E. E. (2003) SKI activates Wnt/b-catenin signaling in human melanoma. Cancer Res. 63, 6626-6634.
33. Kinoshita, M., Nakagawa, T., Shimizu, A., and Katsuoka, Y. (2005) Differently regulated androgen receptor transcriptional complex in prostate cancer compare with normal prostate. Int. J. Urol. 12, 390-397.
34. Wang, J., Yang, Y., Xia, H. H., Gu, Q., Lin, M. C., Jiang, B., Peng, Y., Li, G., An, X., Zhang, Y., Zhuang, Z., Zhang, Z., Kung, H. F., and Wong, B. C. (2007) Suppression of FHL2 expression induces cell differentiation and inhibits gastric and colon carcinogenesis. Gastroenterology 132, 1066-1076.
35. Martin, B. T., Kleiber, K., Wixler, V., Raab, M., Zimmer, B., Kaufmann, M., and Strebhardt, K. (2007) FHL2 regulates cell cycle-dependent and doxorubicin-induced p21Cip1/Waf1 expression in breast cancer cells. Cell Cycle 6, 1779-1788.
36. Kang, Y., Siegel, P. M., Shu, W., Drobnjak, M., Kakonen, S. M., Cordón-Cardo, C., Guise, T. A., and Massagué, J. (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549.
37. Miyaki, M., and Kuroki, T. (2003) Role of Smad4 (DPC4) inactivation in human cancer. Biochem. Biophys. Res. Commun. 306, 799-804.